1. Home
  2. VIRT vs BEAM Comparison

VIRT vs BEAM Comparison

Compare VIRT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtu Financial Inc.

VIRT

Virtu Financial Inc.

HOLD

Current Price

$42.85

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$25.30

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIRT
BEAM
Founded
2008
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.7B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
VIRT
BEAM
Price
$42.85
$25.30
Analyst Decision
Hold
Buy
Analyst Count
7
13
Target Price
$43.71
$51.00
AVG Volume (30 Days)
928.1K
1.7M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
2.31%
N/A
EPS Growth
72.73
82.31
EPS
5.13
N/A
Revenue
$3,632,118,000.00
$24,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.41
$39.64
P/E Ratio
$8.12
N/A
Revenue Growth
26.25
33.33
52 Week Low
$31.55
$13.53
52 Week High
$45.77
$36.44

Technical Indicators

Market Signals
Indicator
VIRT
BEAM
Relative Strength Index (RSI) 64.30 44.10
Support Level $42.53 $23.42
Resistance Level $42.90 $25.69
Average True Range (ATR) 1.21 1.29
MACD 0.01 -0.12
Stochastic Oscillator 96.33 23.31

Price Performance

Historical Comparison
VIRT
BEAM

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: